Targeting DNA repair has become one of the major strategies in modern oncology. The success of PARP inhibitors showed that some tumors can become highly dependent on specific repair pathways to survive, particularly when other DNA repair mechanisms are already impaired.
That success also pushed researchers to look more broadly at how cancer cells respond to DNA damage and replication stress. Many tumors accumulate genetic instability as they grow, forcing them to rely heavily on cell-cycle checkpoints that help repair damage before division. One of the proteins involved in that process is WEE1, a kinase that regulates the transition into mitosis.
The idea behind WEE1 inhibition is that by blocking this checkpoint, cancer cells carrying high levels of DNA damage may be pushed into premature division before repair can occur. The approach already generated interest in the past, but early clinical programs also faced toxicity issues.
Now, interest in the field is picking up again. Newer WEE1 inhibitors are being developed with a stronger focus on selectivity, biomarker-defined patient populations, and combination strategies designed to improve tolerability. More broadly, the field reflects oncology’s growing interest in targeting replication stress vulnerabilities beyond the settings where PARP inhibitors first proved successful.
Table of contents
Why WEE1 became an oncology target
WEE1 became interesting in oncology because of its role in cell-cycle control. The protein is a kinase involved in the G2/M checkpoint, one of the points at which a cell can pause before entering mitosis. When DNA damage is detected, WEE1 helps hold the cell back by inhibiting CDK1, giving the cell more time to repair damage before it divides.
Healthy cells also need this pathway to protect themselves, but the therapeutic logic comes from the way cancer cells behave specifically. Tumor cells divide rapidly, accumulate DNA damage, and experience replication stress. They might often present defects in other pathways, which can weaken the G1 checkpoint earlier in the cycle.
The appeal of WEE1 is that it constitutes a backup system. If a tumor cell loses effective G1 control, it may rely more on later checkpoints to avoid entering replication with damaged DNA. Blocking WEE1 can remove a layer of protection against abnormal mitosis. WEE1 inhibition pushes cancer cells through the cell cycle before they are ready, leading to DNA damage accumulation, replication, and at the end, cell death.
This is why early interest in WEE1 inhibition was closely linked to p53-deficient tumors. The logic was that cells lacking p53 would be more dependent on the G2/M checkpoint and therefore more vulnerable to WEE1 blockade. Today, researchers are also looking at broader markers of replication stress, including alterations linked to cyclin E activity and other DNA damage response defects, to identify tumors that may be especially sensitive to WEE1 inhibition.
The first generation of WEE1 inhibitors: promise meets toxicity
The first serious candidate in WEE1 inhibition was adavosertib (AZD1775), a WEE1 inhibitor developed by AstraZeneca. It became the reference because it moved furthest in the clinic and showed what WEE1 inhibition could do in patients.
By disabling a checkpoint that cancer cells use to cope with DNA damage, adavosertib could make tumors more vulnerable to treatments that already damage DNA, including chemotherapy and radiotherapy. It also made sense to test it alongside other DNA damage response drugs, such as PARP inhibitors, where the aim was to increase pressure on tumors already struggling to repair their genome.
Unfortunately, the program faced the main difficulty of the class, toxicity. WEE1 is not a cancer-specific protein, and normal tissues also use cell-cycle checkpoints, which means the therapeutic window can be narrow.
The first wave showed that biology holds promise. Adavosertib showed clinical activity in several settings, particularly in ovarian and endometrial cancers. In a phase 2 trial in recurrent or persistent uterine serous carcinoma, the drug produced responses in a subset of patients, although the starting dose was not well tolerated.
Why the field is returning now
The field has changed: patient selection is now more precise, new compounds are being designed, and combination strategies have been refined.
The first shift is biomarker selection. Early WEE1 development was influenced by the idea that TP53-mutant tumors would be especially vulnerable, because loss of p53 weakens the G1 checkpoint and may increase reliance on later cell-cycle control. That logic still holds, but it has not been enough on its own. The field is now moving toward narrower populations defined by replication stress and related genomic alterations.
CCNE1 amplification, for example, is a promising target for WEE1 inhibition. Tumors with CCNE1 amplification have high cyclin E activity, which can drive replication stress and make cells more dependent on checkpoint regulation.
That can already be seen in the MYTHIC trial, which is testing combinations built around Repare Therapeutics’ PKMYT1 inhibitor lunresertib and, in one arm, Debiopharm’s WEE1 inhibitor zedoresertib. The trial enrolls patients with advanced solid tumors carrying CCNE1 amplification or deleterious FBXW7 or PPP2R1A alterations.
The second shift is the drug design itself. Aprea Therapeutics is trying to position APR-1051 as a next-generation WEE1 inhibitor with better selectivity than earlier compounds. The company argues that APR-1051 has low off-target inhibition of PLK1, PLK2, and PLK3, a feature it says could help improve tolerability compared with other WEE1 inhibitors. That claim remains early and needs clinical validation, but it indicates that companies are now addressing toxicity.
Then, combination therapies are also part of the equation. WEE1 inhibition makes biological sense with DNA-damaging chemotherapy, PARP inhibitors, and ATR inhibitors. However, these combinations can also amplify toxicity, because normal proliferating tissues are also affected by the same checkpoint pressure.
For biotechs, it is now about matching the right drug to the right tumor, then dosing it in a way that avoids overwhelming normal tissue. This is the balance that could make WEE1 inhibitors a part of a broader precision oncology strategy.
Key companies in the WEE1 inhibitor space
Companies are testing different ways to make the approach more usable, either through better patient selection, more selective molecules, combination strategies, or adjacent checkpoint targets.
One of the most advanced WEE1 programs is Zentalis Pharmaceuticals’ azenosertib. The company is developing it primarily in platinum-resistant ovarian cancer. Zentalis’ phase 2 trial is evaluating azenosertib in platinum-resistant ovarian cancer, and the company has described Cyclin E1-positive disease as the backbone of its regulatory strategy. Topline data are expected by the end of 2026, with potential to support accelerated approval, subject to FDA feedback.
Azenosertib is also a good example of why the WEE1 field remains challenging. In 2024, the U.S. FDA placed several azenosertib studies on partial clinical hold after two patient deaths from presumed sepsis in trial. The hold was lifted later that year.
Aprea Therapeutics is approaching the same problem from a different angle with APR-1051. The company is positioning the candidate as a next-generation WEE1 inhibitor designed to limit off-target kinase inhibition. Aprea argues that APR-1051 has similar WEE1 potency to Zentalis’ azenosertib but substantially lower inhibition of PLK1, PLK2, and PLK3, which it links to the possibility of improved tolerability. That remains a company claim rather than a clinically proven advantage for now, but it speaks to the objective of aiming for more selectivity.
Aprea is also trying to define where APR-1051 might fit clinically through genomically selected tumors. Early data from the ongoing phase 1 study are still preliminary, but the company has reported partial responses in uterine/endometrial cancer with PPP2R1A alterations and stable disease in colorectal cancer with FBXW7 mutation, among other signals.
The field is also expanding beyond WEE1 alone. Repare Therapeutics’ lunresertib, now licensed to Debiopharm, targets PKMYT1, another cell-cycle kinase involved in controlling entry into mitosis. Debiopharm is testing lunresertib with its WEE1 inhibitor zedoresertib in the phase 1 trial. This combination is especially relevant because it targets genomically defined tumors with CCNE1 amplification or deleterious FBXW7 or PPP2R1A alterations, placing it squarely in the replication-stress strategy that now surrounds WEE1.
Early data presented at AACR 2026 showed an overall disease control rate of 68.5%, with more significant activity in ovarian cancer patients carrying CCNE1 or FBXW7 alterations.
The field is still developing, and many of the same questions that limited the first generation remain unresolved. But the strategy around WEE1 inhibition has become more precise. Companies are narrowing development toward replication-stress-dependent cancers, more selective compounds, and combinations designed around tolerability as well as efficacy.
